Home β€Ί Healthcare β€Ί Vaccines β€Ί Global Pediatric Vaccine Market

Global Pediatric Vaccine Market Size, Share, Opportunities, And Trends By Vaccine Type (Monovalent, Multivalent), By Technology (Live-attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Polysaccharide, And Conjugate Vaccines, Toxoid Vaccines, Others), By Application (Infectious Diseases, Cancer, Allergies), And By Geography - Forecasts From 2024 To 2029

πŸ“₯ Download Free SampleπŸ’¬ Speak to Analyst
$3,950
Single User License
Access Full Insights
Report OverviewSegmentationTable of ContentsCustomize Report

Table of Contents

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. GLOBAL PEDIATRIC VACCINE MARKET BY VACCINE TYPE

5.1. Introduction

5.2. Monovalent

5.2.1. Market Opportunities and Trends

5.2.2. Growth Prospects

5.2.3. Geographic Lucrativeness

5.3. Multivalent

5.3.1. Market Opportunities and Trends

5.3.2. Growth Prospects

5.3.3. Geographic Lucrativeness

6. GLOBAL PEDIATRIC VACCINE MARKET BY TECHNOLOGY

6.1. Introduction

6.2. Live-attenuated vaccines

6.2.1. Market Opportunities and Trends

6.2.2. Growth Prospects

6.2.3. Geographic Lucrativeness

6.3. Inactivated vaccines

6.3.1. Market Opportunities and Trends

6.3.2. Growth Prospects

6.3.3. Geographic Lucrativeness

6.4. Subunit, recombinant, polysaccharide, and conjugate vaccines

6.4.1. Market Opportunities and Trends

6.4.2. Growth Prospects

6.4.3. Geographic Lucrativeness

6.5. Toxoid vaccines

6.5.1. Market Opportunities and Trends

6.5.2. Growth Prospects

6.5.3. Geographic Lucrativeness

6.6. Others

6.6.1. Market Opportunities and Trends

6.6.2. Growth Prospects

6.6.3. Geographic Lucrativeness

7. GLOBAL PEDIATRIC VACCINE MARKET BY APPLICATION

7.1. Introduction

7.2. Infectious Diseases

7.2.1. Market Opportunities and Trends

7.2.2. Growth Prospects

7.2.3. Geographic Lucrativeness

7.3. Cancer

7.3.1. Market Opportunities and Trends

7.3.2. Growth Prospects

7.3.3. Geographic Lucrativeness

7.4. Allergies

7.4.1. Market Opportunities and Trends

7.4.2. Growth Prospects

7.4.3. Geographic Lucrativeness

8. GLOBAL PEDIATRIC VACCINE MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Vaccine Type

8.2.2. By Technology

8.2.3. By Application

8.2.4. By Country

8.2.4.1. USA

8.2.4.1.1. Market Opportunities and Trends

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Opportunities and Trends

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Opportunities and Trends

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Vaccine Type

8.3.2. By Technology

8.3.3. By Application

8.3.4. By Country 

8.3.4.1. Brazil

8.3.4.1.1. Market Opportunities and Trends

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Opportunities and Trends

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Opportunities and Trends

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Vaccine Type

8.4.2. By Technology

8.4.3. By Application

8.4.4. By Country

8.4.4.1. Germany

8.4.4.1.1. Market Opportunities and Trends

8.4.4.1.2. Growth Prospects

8.4.4.2. France

8.4.4.2.1. Market Opportunities and Trends

8.4.4.2.2. Growth Prospects

8.4.4.3. United Kingdom

8.4.4.3.1. Market Opportunities and Trends

8.4.4.3.2. Growth Prospects

8.4.4.4. Spain

8.4.4.4.1. Market Opportunities and Trends

8.4.4.4.2. Growth Prospects

8.4.4.5. Others

8.4.4.5.1. Market Opportunities and Trends

8.4.4.5.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Vaccine Type

8.5.2. By Technology

8.5.3. By Application

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Opportunities and Trends

8.5.4.1.2. Growth Prospects

8.5.4.2. Israel

8.5.4.2.1. Market Opportunities and Trends

8.5.4.2.2. Growth Prospects

8.5.4.3. Others

8.5.4.3.1. Market Opportunities and Trends

8.5.4.3.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Vaccine Type

8.6.2. By Technology

8.6.3. By Application

8.6.4. By Country

8.6.4.1. China

8.6.4.1.1. Market Opportunities and Trends

8.6.4.1.2. Growth Prospects

8.6.4.2. Japan

8.6.4.2.1. Market Opportunities and Trends

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Opportunities and Trends

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Opportunities and Trends

8.6.4.4.2. Growth Prospects

8.6.4.5. Indonesia

8.6.4.5.1. Market Opportunities and Trends

8.6.4.5.2. Growth Prospects

8.6.4.6. Others

8.6.4.6.1. Market Opportunities and Trends

8.6.4.6.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. GlaxoSmithKline Plc

10.2. Merck Sharp & Dohme Corp.

10.3. Sanofi

10.4. Pfizer Inc.

10.5. Serum Institute of India Pvt. Ltd.

10.6. AstraZeneca

10.7. Seqirus (CSL Limited)

REPORT DETAILS

Report ID:KSI061611923
Published:May 2024
Pages:130
Format:PDF, Excel, PPT, Dashboard
πŸ“₯ Download SampleπŸ“ž Speak to AnalystπŸ“§ Request Customization

Need Assistance?

Our research team is available to answer your questions.

Contact Us